Target TSH and Free T4 Levels in Graves' Disease
During Active Treatment with Antithyroid Drugs
The primary goal during antithyroid drug therapy is to maintain free T4 at or slightly above the upper limit of normal while TSH remains suppressed. 1
Key Treatment Targets
- Free T4 should be kept at or slightly above the upper limit of the normal reference range (not in the middle or lower normal range). 1
- TSH will remain suppressed below the lower limit of normal for weeks to months after free T4 normalizes, and this suppression does not indicate inadequate treatment. 1, 2
- Total T3 should also be monitored and normalized, particularly in the initial treatment phase when T3 may remain elevated despite normal free T4. 1, 2
Monitoring Schedule
- During the first 3-4 weeks: Measure free T4 ± free T3 monthly until euthyroid status is achieved; TSH is not useful during this phase because it remains suppressed despite normalization of thyroid hormones. 2, 3
- After achieving euthyroidism: Monitor TSH and free T4 every 2-3 months with adapted-dose protocols, or every 3-4 months with block-and-replace protocols. 2, 3
- TSH becomes a reliable monitoring parameter only after it normalizes, which typically occurs 1-3 months after free T4 and T3 have stabilized in the normal range. 2, 3
Special Considerations During Pregnancy
In pregnant women with Graves' disease, targets are deliberately shifted to maintain mild maternal hyperthyroidism to avoid fetal hypothyroidism. 1
Pregnancy-Specific Targets
- Free T4 should be maintained at or slightly above the upper limit of the non-pregnant reference range (or total T4 at 1.5× the non-pregnant upper limit). 1
- TSH should remain suppressed throughout pregnancy while on antithyroid drugs. 1
- Monthly monitoring is mandatory with dose adjustments to maintain these targets. 1
Critical Pitfalls to Avoid
- Do not aim for normal TSH during active antithyroid drug treatment—TSH suppression persists for weeks to months after thyroid hormones normalize and does not indicate treatment failure. 2, 3, 4
- Do not rely on TSH alone for monitoring in the first 1-3 months of treatment—free T4 and total T3 are the primary parameters for dose adjustment during this period. 2, 3
- In Graves' ophthalmopathy, avoid iatrogenic hypothyroidism at all costs—even transient low free T4 can worsen eye disease, so maintain free T4 in the upper-normal range. 2
- TSH suppression reflects circulating TSH-receptor antibody levels more reliably than thyroid hormone concentrations—a suppressed TSH with normal free T4 indicates persistent autoimmune activity, not overtreatment. 4
Rationale for Upper-Normal Free T4 Targets
The recommendation to maintain free T4 at or slightly above the upper limit of normal (rather than mid-normal) is based on several considerations:
- Antithyroid drugs work by blocking new hormone synthesis, so maintaining slightly elevated free T4 ensures adequate circulating hormone while the gland is under pharmacologic suppression. 3
- TSH remains suppressed by persistent TSH-receptor antibodies even when thyroid function normalizes, so targeting mid-normal free T4 risks inducing iatrogenic hypothyroidism. 4
- In pregnancy, fetal thyroid development depends on maternal T4 transfer in early gestation, making maternal hyperthyroxinemia protective rather than harmful. 1
End-of-Treatment Assessment
- Before discontinuing antithyroid drugs after 12-18 months, TSH should be within the normal range (not just detectable but fully normalized). 2, 3
- Measure TSH-receptor antibodies at the end of treatment—elevated TRAb predicts 50% or higher relapse risk and may warrant continued therapy or definitive treatment. 3
- After drug discontinuation, monitor TSH and free T4 every 1-3 months for 6-12 months to detect early relapse. 3